Founded in 2019, TORL BioTherapeutics discovers and develops antibody-based immunotherapies aimed at improving outcomes for cancer patients worldwide. Its lead program, TORL-1-23, is a Claudin 6-targeted antibody-drug conjugate (ADC) currently being evaluated in a registrational Phase 2 study (CATALINA-2) for platinum-resistant ovarian cancer and in Phase 1 for multiple other CLDN6-positive solid tumors such as non-small cell lung, testicular and endometrial cancers. TORL-1-23 has received FDA Fast Track Designation, and the company plans to launch a confirmatory Phase 3 trial (CATALINA-3) in 2026. Proceeds from recent financings will also fund additional Phase 2/3 trials and IND-enabling work on a broader pipeline of novel solid-tumor and hematologic targets. Through a longstanding collaboration with UCLA’s Slamon Research Lab, TORL holds exclusive rights to a large suite of biologics programs. Since inception, TORL has raised more than $450 million to support its clinical and preclinical efforts.

Total raised

$412M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2025